Mark Collins

Mark A Collins, Ph.D. has spent 40 years trying to teach computers to help humans discover better drugs. Mark has held senior roles at the intersection of software; artificial intelligence; drug discovery and business in startup biotech, large pharma and tech companies; and has founded and grown several startups to successful exits. Mark is currently chief scientific officer at Undaunted Bio, a clinical-stage startup using an AI-driven reverse translation approach to repurposing drugs for neuropathic pain. Mark also helps mentor startups in the LifeX accelerator and provides technical input to the LifeX Ventures due diligence team.

Photo of Mark Collins